3rd Quarter - Report

CALIFORNIA LIFE SCIENCES for CALIFORNIA LIFE SCIENCES

Firm
Client
Income
—
Expenses
$160,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Oppose medical device tariffs. Support data exclusivity provisions in USMCA / Oppose proposals to reduce data exclusivity.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
MOLLY FISHMAN —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Taxation/Internal Revenue Code TAX

Support repeal of medical device tax. Support orphan drug tax credit and R & D tax credit.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
MOLLY FISHMAN —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); SENATE

Medical/Disease Research/Clinical Labs MED

Support NIH research funding. Support implementation of 21st Century Cures Act.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
MOLLY FISHMAN —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE

Copyright/Patent/Trademark CPT

Address concerns with provisions of patent litigation reform, including inter partes review. Support STRONGER Patents Act. Support Hatch Waxman Integrity Act. Oppose "march-in" rights and "compulsory licensing" proposals.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
MOLLY FISHMAN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Health Issues HCR

Support FDA user fee programs and review process consistency and predictability. Support PAHPA reauthorization. Support policy improvements to address antimicrobial resistance.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
MOLLY FISHMAN —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; Food & Drug Administration (FDA)

Medicare/Medicaid MMM

Address concerns with changes to Medicare Part B and Part D programs, and Hospital Outpatient Prospective Payment System. Address concerns with Medicare Advantage step therapy proposal and Medicare Part D protected classes proposal. Support Advancing Access to Precision Medicine Act. Oppose changes to Medicare Advantage and Part D prescription drug benefit. Support reforms to enable Value Based Healthcare. Oppose International Pricing Index/reference pricing in Medicare Part B. Support Ensuring Patient Access to/coverage of critical breakthrough products via Hospital Inpatient Prospective Payment System proposed rule and legislation. Oppose Medicare negotiating proposals that include compulsory licensing.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
MOLLY FISHMAN —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Budget/Appropriations BUD

Labor/HHS/Ed Appropriations: NIH, antimicrobial resistance, biodefense/pandemic, science/math education, and strategic stockpile funding and preparation; FDA Appropriations; PTO Appropriations

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
MOLLY FISHMAN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.